IKKα Inhibition Re-sensitizes Acquired Adriamycin-resistant Triple Negative Breast Cancer Cells to Chemotherapy-induced Apoptosis

Overview

Journal Sci Rep

Specialty Science

Date 2023 Apr 17

PMID 37069240

Authors

Jian Liao

Qing-Hong Qin

Fa-You Lv

Zhen Huang

Bin Lian

Chang-Yuan Wei

Qin-Guo Mo

Qi-Xing Tan

Affiliations

Soon will be listed here.

Abstract

IKKα has been shown to be responsible of multiple pro-tumorigenic functions and therapy resistance independent of canonical NF-κB, but its role in acquired chemotherapy resistance in breast cancer remains unclarified. In this study, we obtained pre-treatment biopsy and post-treatment mastectomy specimens from a retrospective cohort of triple-negative breast cancer (TNBC) patients treated with neoadjuvant chemotherapy(NAC) (n = 43). Immunohistochemical methods were used to detect the expression of IKKα before and after NAC, and the relationship between IKKα and the pathologic response to NAC was examined. In addition, we developed a new ADR-resistant MDA-MB-231 cell line(MDA-MB-231/ADR) and analyzed these cells for changes in IKKα expression, the role and mechanisms of the increased IKKα in promoting drug resistance were determined in vitro and in vivo. We demonstrated that the expression of IKKα in residual TNBC tissues after chemotherapy was significantly higher than that before chemotherapy, and was positively correlated with lower pathological reaction. IKKα expression was significantly higher in ADR-resistant TNBC cells than in ADR-sensitive cells, IKKα knockdown results in apoptotic cell death of chemoresistant cells upon drug treatment. Moreover, IKKα knockdown promotes chemotherapeutic drug-induced tumor cell death in an transplanted tumor mouse model. Functionally, we demonstrated that IKKα knockdown significantly upregulated the expression of cleaved caspase 3 and Bax and inhibited the expression of Bcl-2 upon ADR treatment. Our findings highlighted that IKKα exerts an important and previously unknown role in promoting chemoresistance in TNBC, combining IKKα inhibition with chemotherapy may be an effective strategy to improve treatment outcome in chemoresistant TNBC patients.

References

Niu J, Xue A, Chi Y, Xue J, Wang W, Zhao Z . Induction of miRNA-181a by genotoxic treatments promotes chemotherapeutic resistance and metastasis in breast cancer. Oncogene. 2015; 35(10):1302-1313. PMC: 4666837. DOI: 10.1038/onc.2015.189. View

Denkert C, Liedtke C, Tutt A, von Minckwitz G . Molecular alterations in triple-negative breast cancer-the road to new treatment strategies. Lancet. 2016; 389(10087):2430-2442. DOI: 10.1016/S0140-6736(16)32454-0. View

Pan R, Ruvolo V, Mu H, Leverson J, Nichols G, Reed J . Synthetic Lethality of Combined Bcl-2 Inhibition and p53 Activation in AML: Mechanisms and Superior Antileukemic Efficacy. Cancer Cell. 2017; 32(6):748-760.e6. PMC: 5730338. DOI: 10.1016/j.ccell.2017.11.003. View

Haddad S, Abanades Lazaro I, Fantham M, Mishra A, Silvestre-Albero J, Osterrieth J . Design of a Functionalized Metal-Organic Framework System for Enhanced Targeted Delivery to Mitochondria. J Am Chem Soc. 2020; 142(14):6661-6674. PMC: 7146860. DOI: 10.1021/jacs.0c00188. View

Bednarski B, Ding X, Coombe K, Baldwin A, Kim H . Active roles for inhibitory kappaB kinases alpha and beta in nuclear factor-kappaB-mediated chemoresistance to doxorubicin. Mol Cancer Ther. 2008; 7(7):1827-35. PMC: 2581801. DOI: 10.1158/1535-7163.MCT-08-0321. View

Colomer C, Margalef P, Villanueva A, Vert A, Pecharroman I, Sole L . IKKα Kinase Regulates the DNA Damage Response and Drives Chemo-resistance in Cancer. Mol Cell. 2019; 75(4):669-682.e5. PMC: 6715775. DOI: 10.1016/j.molcel.2019.05.036. View

Chen Y, Feng X, Hu X, Sha J, Li B, Zhang H . Dexmedetomidine Ameliorates Acute Stress-Induced Kidney Injury by Attenuating Oxidative Stress and Apoptosis through Inhibition of the ROS/JNK Signaling Pathway. Oxid Med Cell Longev. 2018; 2018:4035310. PMC: 6140004. DOI: 10.1155/2018/4035310. View

Colomer C, Pecharroman I, Bigas A, Espinosa L . Targeting IKKα kinase to prevent tumor progression and therapy resistance. Cancer Drug Resist. 2022; 3(3):482-490. PMC: 8992499. DOI: 10.20517/cdr.2019.104. View

Chenxu G, Minxuan X, Yuting Q, Tingting G, Jinxiao L, Mingxing W . iRhom2 loss alleviates renal injury in long-term PM2.5-exposed mice by suppression of inflammation and oxidative stress. Redox Biol. 2018; 19:147-157. PMC: 6118040. DOI: 10.1016/j.redox.2018.08.009. View

10.

Bell E, Chakraborty A, Mo X, Liu Z, Shilo K, Kirste S . SMARCA4/BRG1 Is a Novel Prognostic Biomarker Predictive of Cisplatin-Based Chemotherapy Outcomes in Resected Non-Small Cell Lung Cancer. Clin Cancer Res. 2015; 22(10):2396-404. PMC: 4867280. DOI: 10.1158/1078-0432.CCR-15-1468. View

11.

Vreka M, Lilis I, Papageorgopoulou M, Giotopoulou G, Lianou M, Giopanou I . IκB Kinase α Is Required for Development and Progression of -Mutant Lung Adenocarcinoma. Cancer Res. 2018; 78(11):2939-2951. PMC: 6485619. DOI: 10.1158/0008-5472.CAN-17-1944. View

12.

Gang E, Kim H, Hsieh Y, Ruan Y, Ogana H, Lee S . Integrin α6 mediates the drug resistance of acute lymphoblastic B-cell leukemia. Blood. 2020; 136(2):210-223. PMC: 7357190. DOI: 10.1182/blood.2019001417. View

13.

Shukla S, Purohit V, Mehla K, Gunda V, Chaika N, Vernucci E . MUC1 and HIF-1alpha Signaling Crosstalk Induces Anabolic Glucose Metabolism to Impart Gemcitabine Resistance to Pancreatic Cancer. Cancer Cell. 2017; 32(1):71-87.e7. PMC: 5533091. DOI: 10.1016/j.ccell.2017.06.004. View

14.

Guo D, Xu P, Chen D, Wang L, Zhu Y, Zuo Y . Daunorubicin-Loaded CdTe QDs Conjugated with Anti-CD123 mAbs: A Novel Delivery System for Myelodysplastic Syndromes Treatment. Int J Nanomedicine. 2020; 15:521-536. PMC: 6988587. DOI: 10.2147/IJN.S233395. View

15.

Livak K, Schmittgen T . Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2002; 25(4):402-8. DOI: 10.1006/meth.2001.1262. View

16.

Wang W, Kryczek I, Dostal L, Lin H, Tan L, Zhao L . Effector T Cells Abrogate Stroma-Mediated Chemoresistance in Ovarian Cancer. Cell. 2016; 165(5):1092-1105. PMC: 4874853. DOI: 10.1016/j.cell.2016.04.009. View

17.

Dong W, Li Y, Gao M, Hu M, Li X, Mai S . IKKα contributes to UVB-induced VEGF expression by regulating AP-1 transactivation. Nucleic Acids Res. 2011; 40(7):2940-55. PMC: 3326327. DOI: 10.1093/nar/gkr1216. View

18.

Colomer C, Marruecos L, Vert A, Bigas A, Espinosa L . NF-κB Members Left Home: NF-κB-Independent Roles in Cancer. Biomedicines. 2017; 5(2). PMC: 5489812. DOI: 10.3390/biomedicines5020026. View

19.

Wang W, Liu W, Huang D, Jia W, Ji C, Hu B . Targeting PCDH20 gene by microRNA-122 confers 5-FU resistance in hepatic carcinoma. Am J Cancer Res. 2016; 6(8):1681-94. PMC: 5004072. View

20.

Leung L, Wang T . Differential effects of chemotherapeutic agents on the Bcl-2/Bax apoptosis pathway in human breast cancer cell line MCF-7. Breast Cancer Res Treat. 1999; 55(1):73-83. DOI: 10.1023/a:1006190802590. View